We are live on ! Find out more
ELOX

Eloxx Pharmaceuticals, Inc. Common Stock
ELOX

Delisted

ELOX was delisted on the 13th of October, 2023.

Back to rankings

19 hedge funds and large institutions have $672K invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $477K → $672K (+$195K)

0% more funds holding

Funds holding: 19 → 19 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
+$98.4K
2
UBS Group
UBS Group
Switzerland
+$1.25K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$159
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$105

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$71.4K
2
Bank of America
Bank of America
North Carolina
-$5.71K
3
TRCT
Tower Research Capital (TRC)
New York
-$4.96K
4
Morgan Stanley
Morgan Stanley
New York
-$4
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Silverarc Capital Management
Massachusetts
$136K +$98.4K +27,199 +101%
MMH
2
Menora Mivtachim Holdings
Israel
$131K – – –
AFG
3
American Financial Group
Ohio
$93K – – –
HIIFS
4
Harel Insurance Investments & Financial Services
Israel
$74K – – –
AS
5
Altshuler Shaham
Israel
$63.1K – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$51.9K -$71.4K -19,727 -49%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$50.8K +$159 +44 +0.2%
CI
8
Clal Insurance
Israel
$37K – – –
BlackRock
9
BlackRock
New York
$22.3K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$7K -$4.96K -1,372 -36%
Wells Fargo
11
Wells Fargo
California
$2.93K – – –
UBS Group
12
UBS Group
Switzerland
$1.18K +$1.25K +346 +281%
Bank of America
13
Bank of America
North Carolina
$931 -$5.71K -1,578 -81%
Morgan Stanley
14
Morgan Stanley
New York
$198 -$4 -1 -1%
MAM
15
Meeder Asset Management
Ohio
$38 – – –
Group One Trading
16
Group One Trading
Illinois
$10 – – –
NC
17
NewSquare Capital
Pennsylvania
$3 – – –
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
– +$105 +29 +207%

ELOX Hedge Fund Activity: Q1 2023 in Review

19 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q1 2023, worth a combined $672K — up 41% from $477K a quarter earlier.

Fund positioning in ELOX was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Silverarc Capital Management, adding an estimated $98.4K. The largest seller was Vanguard Group, cutting an estimated $71.4K.

  • 19 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $672K of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q1 2023, up 41% quarter-over-quarter.
  • 0 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 0 closed out.
  • The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Silverarc Capital Management, an estimated $98.4K added.
  • The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Vanguard Group, an estimated $71.4K sold.

Based on aggregated 13F filings for Q1 2023.